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a b s t r a c t   
In post-mortem investigations of fatal intoxication, it is challenging to determine which drug(s) were re-
sponsible for the death, and which drugs did not. This study aims to provide post-mortem femoral blood 
drug levels in lethal intoxication and in post-mortem control cases, where the cause of death was other than 
intoxication. The reference values could assist in the interpretation of toxicological results in the routine 
casework. 
To this end, all post-mortem toxicological results in femoral blood from 2011 to 2017 in Western 
Switzerland were considered. A full autopsy with systematic toxicological analysis (STA) was conducted in 
all cases. Results take into account the cause of death classified into one of four categories (as published by 
Druid and colleagues): I) certified intoxication by one substance alone, IIa) certified intoxication by more 
than one substance, IIb) certified other causes of death with incapacitation due to drugs, and III) certified 
other causes of death without incapacitation due to drugs. 
This study includes 1 990 post-mortem cases where femoral blood was analysed. The material comprised 
619 women (31%) and 1 371 men (69%) with a median age of 50 years. The concentrations of the 32 most 
frequently recorded substances as well as alcohol are discussed. These include 6 opioids and opiates, 3 
antidepressants, 6 neuroleptics and hypnotics, 1 barbiturate, 11 benzodiazepines (and related drugs), 2 
amphetamine-type stimulants, cocaine, paracetamol, and tetrahydrocannabinol (THC). 
The most common substances that caused intoxication alone were morphine, methadone, ethanol, 
tramadol, and cocaine. The post-mortem concentration ranges for all substance are categorized as I, IIa, IIb, 
or III. Statistical post-mortem reference concentrations for drugs are discussed and compared with pre-
viously published concentrations. This study shows that recording and classifying cases is time-consuming, 
but it is rewarding in a long-term perspective to achieve a more reliable information about fatal and 
non-fatal blood concentrations. 
© 2021 The Authors. Published by Elsevier B.V. 
CC_BY_4.0   
1. Introduction 
Post-mortem toxicology involves detecting and quantifying cer-
tified toxic, or potentially toxic, substances in whole blood obtained 
from a full autopsy. The measured concentration plays a major role 
in the interpretation process that contributes towards the determi-
nation of the cause of death. Although this alone is not sufficient, 
factors including clinical history and other autopsy findings, and 
results of supplementary analyses, circumstances surrounding the 
death, diseases, alcohol and substance abuse history etc… should be 
taken into account. Reference databases on therapeutic and toxic 
concentration in human are often used as an aid to interpretation  
[1–4]. However, these concentrations must be used carefully if they 
are to be considered for post-mortem cases, principally because of 
possible post-mortem drug redistribution [5–8]. Due to this phe-
nomenon, these data need to be supplemented by post-mortem 
concentrations rates [9,10]. 
While case reports and small case series could be used to a cer-
tain extent, these data are often heterogeneous in terms of the origin 
of the blood samples analyzed (e.g. femoral or cardiac) and based 
only on one or a short series of exceptional cases with high con-
centrations of drugs. In addition, one single case report cannot be 
generalized to the whole population since the individual’s response 
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to the drug (e.g. tolerance) and substance interaction needs to be 
taken into account. The alternative approach presented here consists 
of taking into account all the cases in which drugs and/or alcohol 
were detected. 
This approach has been developed for several years in Sweden  
[9]. Druid and colleagues show that blood, sampling, processing, 
analysis and review of post-mortem drug concentrations using a 
standardized protocol is one of the most powerful tools to enhance 
toxicological interpretation [9,10]. In these published papers, cases 
are subdivided into three post-mortem groups: poisoning by one 
substance only (group A), multi-substance poisoning (group B) and 
deaths not involving incapacitation (group C). Druid and colleagues 
also compared the results of these three groups with the con-
centrations obtained from cases of driving under the influence and 
concentrations observed in therapeutic drug monitoring cases. An-
other study conducted by Launiainen, Ketola & Ojanperä, followed 
an all-causes-of-death approach, which means that they did not split 
the data into post-mortem groups based on the causes of death. 
Such an approach offers an idea of the concentration ranges to ex-
pected for different drugs, which are valuable for laboratories 
planning to set up verification methods, and does not require a 
manual review of the cases, but the drawback is that a certain cut-off 
of e.g. 95% for toxic concentrations may be reasonable for some drugs, 
but higher or lower cut-offs may apply for other drugs [11–13]. 
In this present paper, the approach developed is one using the 
groupings presented by Druid and colleagues [9]. In Western Swit-
zerland, when the legal authorities require a full-autopsy, tox-
icological investigations are performed at the University Centre of 
Legal Medicine (CURML) - located at the University Hospitals of 
Lausanne and Geneva. 
From 2011–2017, all cases where drugs and/or alcohol con-
centrations were measured in post-mortem femoral whole blood 
were collected and divided into several groups according to the 
certified causes of deaths. The aim of this study is to provide blood 
reference concentrations observed in lethal intoxications and in 
post-mortem control cases for 32 substances and alcohol. 
2. Materials and methods 
2.1. Inclusion criteria 
All of the following post-mortem cases involve toxicological in-
vestigations of whole blood obtained from full autopsies performed 
in Western Switzerland (Geneva, Lausanne, Jura, Neuchatel, Fribourg 
and Valais) during a period ranging from 2011 to 2017. 
2.2. Sample collection 
Prior to analysis, femoral blood was sampled in tubes containing 
preservatives, such as Ethylene Diamine Tetra Acetic acid (EDTA) or 
sodium fluoride, and stored at 4 °C. 
2.3. Toxicological analysis 
A systematic toxicological analysis (STA) of therapeutic drugs, 
drugs of abuse, volatiles, cyanide, and pesticides are performed using 
validated analytical procedures. The STA used is based on screening 
procedures and quantification analyses as described in previous 
publications [15–18] and relies on toxicological literature [14,19,20]. 
Screening procedures include immunoassays (Siemens; Specialty Di-
agnostics; Randox) using the manufacturer’s recommended cut-off, 
colour tests (Fujiwara; Cyantesmo), and chromatographic analyses 
which consist of: gas chromatography coupled to mass spectrometry 
(GC-MS, Agilent), liquid chromatography coupled to diode array de-
tectors (HPLC-DAD, Agilent), and head-space gas chromatography 
coupled to flame ionisation detectors (HS-GC-FID, Agilent). Basic, 
acidic and neutral semi-volatile and non-volatile drugs were identi-
fied using commercial libraries [47-50]. When drugs were detected, 
quantitative analyses were performed using GC-MS, HPLC-DAD, 
HS-GC-FID or liquid chromatography coupled to tandem mass spec-
trometry (LC-MS/MS). Some substances, such as carboxyhemoglobin 
(CO-Hb) and gamma-hydroxybutyric acid (GHB), were not included 
in the STA, and their analyses were performed only in the case of 
suspicion of exposure to these substances [21–23]. 
2.4. Selection and classification of cases 
During the six-year study period (1 January 2011 – 31 December 
2017), drug findings in post-mortem femoral blood from 1 990 au-
topsy cases were recorded. A total of 146 drugs were detected at 
least once. For 10 substances, only qualitative data were recorded 
(theobromine, nicotine, cotinine, caffeine, phenacetin, ephedrine, 
etifoxine, etomidate, fluconazole, metoclopramide). As highlighted 
in Söderberg et al.’s work [24], the sample size has an impact on the 
data, therefore the following set limit was chosen. Drugs were se-
lected according to two criteria: (1) the drug had been detected and 
quantified at least 50 times and/or (2) the drug had been involved in 
certified intoxication by one substance (group I, detailed hereafter). 
A total of 32 substances and alcohol correspond to one of the criteria, 
among them, twenty were selected and plotted as boxplots to have a 
better visualization of the data. 
If available, date of birth, date of death, sex, cause of death and 
drugs concentration in post-mortem blood were manually entered in 
a database once anonymized. All causes and manners of death have 
been coded using the International Classification of Diseases 
(ICD-10). Commonly reported codes being Y10-Y19 (poisoning, un-
determined intent), X60-X84 (intentional self-harm), I21-I49 (dis-
eases of the circulatory system, pulmonary and heart diseases), R99 
(defined and unknown causes of mortality), V40-V49 (Transport 
accidents). Other external causes and manners, such as W00-W19 
(Falls), X85-Y09 (Assault), W65-W74 (Accidental drowning and 
submersion), X00-X08 (Exposure to smoke, fire, and flames), J10-J18 
(Influenza and pneumonia), Y21-Y29 (Hanging, drowning, un-
determined intent) and I60-I86 (Cerebrovascular diseases), were 
reported but to a lesser extent. 
The first author coded causes of deaths based on the immediate 
cause of death, and categorized all of the cases into four groups 
based on Druid and colleagues’ work [9,10]: (I) certified intoxication 
by one substance; (IIa) certified intoxication by more than one 
substance; (IIb) certified other causes of death with incapacitation 
due to drugs; and (III) certified other causes of death without in-
capacitation due to drugs. Group III provides an idea of drug con-
centrations that may be observed without causing incapacitation. A 
second author (MA) reviewed the group assignments and database 
inclusions. Any discrepancies were checked against the original data 
to arrive at a consensus. 
For each group, median, minimum, maximum and percentile 
(10th, 25th, 75th and 90th) concentrations (µg/L) were calculated. 
For each drug already published [10,13], concentrations were com-
pared with previous studies. If several drugs were detected, but 
according to the toxicological report only one substance led to the 
death, the case was included in group I (i.e. single drug intoxication), 
and the value of the other drug was deleted. For certified fatal in-
toxications caused by more than one substance (IIa), concentrations 
were counted in all relevant substance groups (for example an in-
toxication involving both zopiclone and oxazepam counted for both). 
To distinguish group IIb and III, the final cause-of-death was ex-
tracted from the autopsy report and if the incapacitation was men-
tioned, cases were recorded in the IIb group: such a group has not 
been formed in Druid’s studies. The purpose of group IIb is to pro-
vide ranges of concentrations observed in deaths by causes other 
than intoxication, but where drugs may have had an impact on the 
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sequences of events that led to the death. Statistical analyses were 
performed using Tableau Desktop 10.4.12 software and R. 
3. Results 
3.1. Socio-demographic characteristics 
From 2011–2017, 1 990 post-mortem cases with femoral blood 
analysed were reported in the study. Sedative, hypnotic or psychoac-
tive drugs (excluding caffeine) were detected in 1 338 cases (67%). 
After assignment in predefined groups, 1 857 cases were included 
to one of the four groups. The 133 (6%) cases that could not be as-
signed were excluded. 115 (6%) cases were attributed to intoxication 
by one drug and/or alcohol (I), 303 (15%) cases related to certified 
intoxication by more than one substance (IIa), 324 (16%) cases were 
related to an external cause of death but drugs and/or alcohol may 
have caused incapacitation (IIb). In addition, 1 115 (56%) cases were 
related to another cause of death without incapacitation by 
drugs (III). 
For all groups, the majority of cases reported were male (I: 55%; 
IIa: 69%; IIb: 76%; III: 69%). In total, the material comprised 619 fe-
males (31%) and 1 371 males (69%) with a median age of 50 years. 
Among the fatal intoxications, the age group 40–49 years was the 
largest group (group I: 29%, 33 cases; group IIa: 27%, 82 cases). The 
distribution of ages in the four groups of deaths are presented in  
Fig. 1. This age range is much lower compared to the death rates 
reported by decennial ages in Canton of Vaud (Western Switzerland; 
DR), where most deaths happen at 80 years or older [25]. 
3.2. Drug concentrations rates in the four groups discrimination 
Table 1 shows the femoral blood concentrations of the 32 psy-
choactive substances selected in alphabetical order. They include, 6 
opioids and opiates (fentanyl, methadone, morphine (free and total), 
oxycodone and tramadol), 3 antidepressants (amitriptyline, trazo-
done and venlafaxine), 6 neuroleptics and hypnotics (amisulpride, 
clomethiazole, clotiapine, clozapine, olanzapine and quetiapine), 
pentobarbital, 11 benzodiazepines and related drugs (alprazolam, 
bromazepam, citalopram, clonazepam, diazepam, lorazepam, 
midazolam, nordiazepam, oxazepam, zolpidem and zopiclone), 
2 amphetamines type stimulants (amphetamine and MDMA), co-
caine, paracetamol and, finally, tetrahydrocannabinol (THC). Among 
these 32 substances, 20 are plotted in Fig. 2 to highlight the differ-
ence between concentrations of the four groups. 
Among the 1 857 cases considered for this study, benzodiazepines 
were detected in 38% (711 cases), antidepressants in 15% (281 cases), 
neuroleptics in 11% (212 cases), opiates in 11% (206 cases, including 
morphine (9.6%)), opioids in 13% (255 cases, including methadone 
(8.1%) and buprenorphine (0.2%)), cocaine in 4.5% (84 cases), sym-
pathomimetics in 2.4% (46 cases, including amphetamines (2.2%)), 
carboxyhemoglobin (CO-Hb ≥ 20%) in 2.1% (40 cases), GHB in 0.2% 
(3 cases), paracetamol in 12% (240 cases), caffeine/theobromine in 
83% (1 543 cases), and nicotine/cotinine in 25% (465 cases). 
In Fig. 2, a graphical representation of the concentrations of 20 of 
the substances are shown. For 3 opioids and opiates (fentanyl, me-
thadone and free morphine), the concentration between the 25th 
percentile and the 75th percentile in group I overlap with the values 
reported in the control groups (IIa, IIb and III). This is particularly the 
case for fentanyl, where 1.5 of the interquartile ranges from 1.0 to 21.0 
for group I overlaps with the 25–75 percentile for group III (1.0–31.0). 
Trazodone, an antidepressant, is also interesting because the median 
(1 360 ug/L) for group I is higher than for the three other groups, but 
the range for group I is broad (from 720 ug/L to 2 000 ug/L) and 
overlapped with group IIa (180 ug/L to 1 300 ug/L). For neuroleptics, 
hypnotics and benzodiazepines, values do not overlap between the 
group I and the three other groups. 
3.3. Alcohol concentration in the four groups 
Among the 1 857 cases considered, 25% of cases (464) contained 
ethanol above the threshold of 0.10 [g/kg] (threshold provided by the 
federal roads office in its road safety ordinance [26]). For group I, 
where deaths are induced by alcohol consumption only, the con-
centrations measured are higher than in the other groups. However, 
an overlap in the data is observed for the three other groups (IIa, IIb, 
III) with the same concentration range from the 25th to the 75th 
percentile.(Table 2). 
4. Discussion 
This study aimed to provide post-mortem femoral blood re-
ference data to support the interpretation of drug concentration in 
post-mortem toxicology investigations. Following the method sug-
gested by Druid and colleagues [9,27–29], the objective was to il-
lustrate the differences between non-toxic and lethal concentration 
detected in femoral blood in post-mortem cases. In order to do so, a 
comparison was made between blood from one-substance poisoning 
(I), multi-substance poisoning (IIa), and from causes of death with 
(IIb) and without (III) incapacitation due to drugs. All the results are 
detailed and discussed below according to the groups defined in the 
result section. (Fig. 3). 
4.1. Concentration of opioids and opiates 
A large variation in post-mortem blood concentrations of opioids 
and opiates have consistently been reported in the literature, which 
can be explained by a large variation in tolerance between subjects. 
This pattern was also observed in the present study. Observations of 
lung edema and froth in the airways are rather a more important key 
to fatal opioid intoxication with the strong mu-opioid receptor 
agonists than their concentrations in post-mortem femoral blood. 
Nevertheless, in this section, the results regarding concentration 
of morphine (free and total), buprenorphine, fentanyl, methadone, 
oxycodone, and tramadol are discussed. Ten cases recorded as cer-
tified intoxication by one substance alone (group I) were related to 
morphine detection (free and total). The detection of morphine in 
blood could be the result of heroin or morphine or codeine con-
sumption. Among these ten cases, seven were related to heroin in-
take (confirmed by the presence of 6-monoacetylmorphine). Both 
free morphine and total morphine concentrations were measured, 
total morphine is calculated based on the concentration of free 
morphine, morphine-3-glucuronide and morphine-6- glucuronide  
[30]. For total morphine, the 25th percentile in the group I (1 028 µg/L) 
is higher than the 75th percentile of group IIa (670 µg/L). This is not 
the case for free morphine (94 µg/L for the 25th percentile of group I, 
240 µg/L for the 75th percentile of group IIa). Since the data does not 
overlap, total morphine appears to be more adequate for interpreting 
Fig. 1. The distribution of ages in single substance intoxication (I), multiple substance 
intoxication (IIa), other cause of death with incapacitation (IIb), and other cause of 
death without incapacitation due to drugs (III); number of deaths by decennial age 
groups, Western Switzerland, Canton de Vaud, sum of the cases between 2011 and 
2017 (death rate, DR [25]). 
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Table 1 
Femoral blood concentrations of 32 substances in post-mortem cases, classified into four groups: I) Certified intoxication by one single substance (N = 115); II a) Certified 
intoxication by a combination of at least two substances (N = 303); II b) Certified other causes of death with incapacitation due to at least one substance (N = 324), III) Certified 
other causes of death without incapacitation (N = 1 115). The Lower Limit of Quantitation LLOQ for each substance is reported.            
Drug group N min 10th 25th median 75th 90th max  
Alprazolam [µg/L] LLOQ 1.5 µg/L I  0        
IIa  42 2 5 14 38 100 170 300 
IIb  22 4 6 13 36 65 81 150 
III  18  < LLOQ 5 7 14 31 49 69 
Total  82  < LLOQ 5 10 29 67 134 300 
Amisulpride [µg/L] LLOQ 20 µg/L I  1 11 300 11 300 11 300 11 300 11 300 11 300 11 300 
IIa  8 160 180 425 1 550 3 500 11 500 19 000 
IIb  3 680 692 710 740 840 900 940 
III  4 130 193 288 470 1 075 1 930 2 500 
Total  16 130 172 405 840 2 375 9 110 19 000 
Amitriptyline [µg/L] LLOQ 20 µg/L I  1 2 900 2 900 2 900 2 900 2 900 2 900 2 900 
IIa  7 22 24 31 330 795 1 520 2 000 
IIb  3 20 22 25 30 290 446 550 
III  6 20 26 35 44 76 210 300 
Total  17 20 21 29 60 430 1 600 2 900 
Amphetamine [µg/L] LLOQ 10 µg/L I  2 450 487 543 635 728 783 820 
IIa  4 10 10 11 26 45 53 58 
IIb  4 12 23 40 67 68 68 68 
III  1 34 34 34 34 34 34 34 
Total  11 10 11 18 50 68 487 820 
Bromazepam [µg/L] LLOQ 5.0 µg/L I  1 11 950 11 950 11 950 11 950 11 950 11 950 11 950 
IIa  30 11 30 69 240 695 1 017 2 500 
IIb  11 5 25 76 160 310 430 480 
III  11 12 33 42 70 119 193 200 
Total  53 5 24 57 175 358 890 11 950 
Citalopram [µg/L] LLOQ 1.0 µg/L I  0        
IIa  56 11 53 93 305 513 1 150 2 800 
IIb  27 34 66 90 250 340 622 2 200 
III  59 17 77 119 235 350 525 940 
Total  143 11 64 110 260 420 882 2 800 
Clomethiazole [µg/L] LLOQ 1.0 µg/L I  0        
IIa  5 16 611 1 504 4 400 9 350 13 940 17 000 
IIb  4 3 500 3 660 3 900 4 300 4 700 4 940 5 100 
III  5        
Total  14 16 1 008 2 375 4 300 6 375 11 900 17 000 
Clonazepam [µg/L] LLOQ 1.0 µg/L I  0        
IIa  39 1.0 1.0 3.0 5.0 6.0 20 48 
IIb  16 2.0 2.0 6.0 11 33 62 72 
III  8 3.0 4.0 6.0 7.0 9.0 28 45 
Total  63 1.0 2.0 3.0 6.0 11 35 72 
Clotiapine [µg/L] LLOQ 1.0 µg/L I  0        
IIa  8 25 32 41 59 103 475 1 000 
IIb  2 74 74 74 74 74 74 74 
III  5 20 28 40 60 114 146 167 
Total  15 20 25 41 60 103 167 1 000 
Clozapine [µg/L] LLOQ 1.0 µg/L I  1 1 130 1 130 1 130 1 130 1 130 1 130 1 130 
IIa  4 633 863 1 208 2 050 4 350 7 320 9 300 
IIb  4 960 1 032 1 140 1 800 2 625 3 030 3 300 
III  1 457 457 457 457 457 457 457 
Total  10 457 615 1 003 1 300 2 625 3 900 9 300 
Cocaine [µg/L] LLOQ 10 µg/L I  6 300 560 1 065 2 525 3 588 7 850 12 000 
IIa  52 10 10 17 28 95 594 2 300 
IIb  19 10 10 19 130 170 680 1 900 
III  7 10 10 20 44 106 170 200 
Total  84 10 10 19 35 200 1 480 12 000 
Diazepam [µg/L] LLOQ 5.0 µg/L I  0        
IIa  28 17 27 41 152 335 426 2 000 
IIb  11 8.0 22 31 79 372 640 1 555 
III  17 10 15 24 70 186 438 660 
Total  56 8.0 20 33 116 308 499 2 000 
Fentanyl [µg/L] LLOQ 0.5 µg/L I  2 1.0 3.0 6.0 12 17 20 22 
IIa  2 3.0 3.0 3.0 4.0 4.0 4.0 4.0 
IIb  4 1.0 2.0 4.0 7.0 14 25 32 
III  8 2.0 2.0 3.0 6.0 21 41 55 
Total  16 1.0 1.0 3.0 5.0 12 31 55 
Lorazepam [µg/L] LLOQ 3.5 µg/L I  1 1 100 1 100 1 100 1 100 1 100 1 100 1 100 
IIa  45  < LLOQ 6.0 17 30 65 169 3 900 
IIb  35  < LLOQ 7.0 11 23 47 113 280 
III  52 5.0 5.0 8.0 16 39 63 160 
Total  133  < LLOQ 5.0 10 23 47 130 3 900 
(continued on next page) 
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Table 1 (continued)           
Drug group N min 10th 25th median 75th 90th max  
MDMA [µg/L] LLOQ 10 µg/L I  1 7 600 7 600 7 600 7 600 7 600 7 600 7 600 
IIa  4 20 35 57 84 399 940 1 300 
IIb  5 31 112 233 495 943 1 397 1 700 
III  1 580 580 580 580 580 580 580 
Total  11 20 30 77 440 1 148 2 290 7 600 
Methadone [µg/L] LLOQ 10 µg/L I  12 190 260 470 1 050 1 300 1 930 2 200 
IIa  101 26 128 238 455 903 1 200 3 400 
IIb  23 26 111 285 437 871 1 100 1 300 
III  13 50 95 155 485 1 125 1 290 1 500 
Total  149 26 122 275 480 950 1 300 3 400 
Midazolam [µg/L] LLOQ 1.5 µg/L I  0        
IIa  45 5.0 10 20 46 120 280 3 500 
IIb  25 7.0 20 29 78 170 370 600 
III  84  < LLOQ 5.0 14 47 94 263 698 
Total  155  < LLOQ 8.0 20 49 115 298 3 500 
Morphine (free) [µg/L] LLOQ 20 µg/L I  10 20 66 94 275 455 2 170 11 800 
IIa  107  < LLOQ  < LLOQ 32 94 240 552 4 700 
IIb  26  < LLOQ  < LLOQ  < LLOQ 26 59 220 1 245 
III  36  < LLOQ  < LLOQ  < LLOQ 80 170 250 670 
Total  179  < LLOQ  < LLOQ 21 83 220 488 11 800 
Morphine (total) [µg/L] LLOQ 20 µg/L I  10 60 375 1 028 1 550 1 850 5 793 21 400 
IIa  111  < LLOQ 22 140 290 708 1 970 13 770 
IIb  28  < LLOQ 11 50 141 270 883 2 500 
III  37  < LLOQ 16 47 159 768 1 978 3 100 
Total  186  < LLOQ 20 85 260 770 2 000 21 400 
Nordiazepam [µg/L] LLOQ 20 µg/L I  0        
IIa  96  < LLOQ 27 83 285 620 1 019 2 300 
IIb  42  < LLOQ 44 67 190 523 950 2 000 
III  39  < LLOQ 23 53 135 280 489 930 
Total  177  < LLOQ 27 67 210 535 958 2 300 
Olanzapine [µg/L] LLOQ 20 µg/L I  0        
IIa  14 68 98 130 180 280 312 600 
IIb  6 20 34 55 74 147 263 340 
III  11  < LLOQ 39 46 60 107 250 300 
Total  31  < LLOQ 43 65 125 251 306 600 
Oxazepam [µg/L] LLOQ 20 µg/L I  1 4 440 4 440 4 440 4 440 4 440 4 440 4 440 
IIa  118  < LLOQ  < LLOQ 25 57 223 880 7 700 
IIb  66  < LLOQ  < LLOQ 30 70 263 760 2 000 
III  68  < LLOQ  < LLOQ 16 57 205 558 1 700 
Total  253  < LLOQ  < LLOQ 24 59 237 828 7 700 
Oxycodone [µg/L] LLOQ 20 µg/L I  2 480 485 493 505 518 525 530 
IIa  9 41 66 100 255 409 2 120 7 600 
IIb  2 29 34 42 56 69 77 82 
III  2 22 26 33 44 55 62 66 
Total  15 22 34 69 110 445 662 7 600 
Paracetamol [mg/L] I  6 30 45 61 109 180 195 200 
IIa  60        
IIb  36        
III  137        
Total  239        
Pentobarbital [µg/L] LLOQ 0.2 µg/L I  7 5 500 6 280 7 750 16 000 25 500 35 000 38 000 
IIa  0        
IIb  0        
III  0        
Total  7 5 500 6 280 7 750 16 000 25 500 35 000 38 000 
Quetiapine [µg/L] LLOQ 1.0 µg/L I  0        
IIa  51 1.0 31 67 250 910 2 120 10 850 
IIb  23 5.0 67 132 195 315 614 1 200 
III  26 5.0 11 27 79 160 270 600 
Total  100 1.0 20 62 160 495 1 380 10 850 
Tetrahydro-cannabinol [µg/L] LLOQ 0.5 µg/L I  0        
IIa  19 1.0 1.0 1.0 3.0 8.0 16 100 
IIb  47 1.0 1.0 2.0 6.0 17 50 126 
III  34 1.0 1.0 4.0 8.0 19 33 290 
Total  100 1.0 1.0 2.0 6.0 15 42 290 
Tramadol [µg/L] LLOQ 10 µg/L I  7 1 400 1 760 2 050 2 700 4 700 5 320 5 800 
IIa  28 10 59 205 600 1 850 3 860 15 000 
IIb  13 10 107 493 830 1 150 1 390 2 000 
III  27 21 70 150 350 550 830 970 
Total  75 10 74 175 600 1 388 2 700 15 000 
Trazodone [µg/L] LLOQ 10 µg/L I  2 720 848 1 040 1 360 1 680 1 872 2 000 
IIa  20 28 94 183 298 1 200 1 720 10 000 
IIb  16  < LLOQ 75 145 300 645 832 1 800 
III  19 69 160 215 390 488 859 1 600 
Total  57  < LLOQ 90 190 360 690 1 560 10 000 
(continued on next page) 
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the post-mortem concentration rates, especially considering that the 
morphine-6-glucuronide could be a more potent analgesic than mor-
phine [31]. Even if the results of the total morphine are more desig-
nated for the post-mortem interpretation, both free and total median 
values for group I are higher than for group IIa (free morphine: 
275 µg/L and 94 µg/L; total morphine: 1 550 µg/L and 285 µg/L, for 
group I and group IIa respectively). 
Only three cases of buprenorphine were recorded in the data-
base. Consequently, this substance is not reported in Table 1. This 
finding is consistent with the fact that in Switzerland, methadone is 
more often prescribed than buprenorphine as part of the opioid 
substitution treatment [32]. Methadone was detected in 129 cases 
during the studied period (1 January 2011 – 31 December 2017), 
with 12 cases where intoxication was related to methadone intake 
only. An overlap was found between the methadone concentrations 
which had caused an intoxication and those which were incidental 
findings (groups I and IIa vs IIb and III). This result could be ex-
plained by the variability in each individual’s response to the drug 
(addiction and tolerance). Due to this overlap, particular precautions 
need to be taken for interpreting the result of opioids, such as bu-
prenorphine and methadone, post-mortem concentration by itself 
has a limited role in assessing the cause of death and the clinical 
history of the deceased need to be taken into account. The same 
methadone dose in two different individuals could be potentially 
inadequate to mask the side-effect of heroin cessation (clinical ef-
fective dose required) or fatal [33,34]. The same observation can be 
made for tramadol, for which the overlap observed between groups 
is related to the individual’s tolerance to opioids. 
In addition, fentanyl is highly potent and a small dose variation 
can lead to serious consequences, thus explaining the overlap 
between concentrations in the four groups. 
Finally, for oxycodone, the 10th percentile of concentration in 
group I (485 µg/L) is higher than the 75th percentile of group IIa 
(409 µg/L), and the concentration rate of group III is the lowest (with 
the 90th percentile at 62 µg/L). This finding seems to suggest the 
existence of differences between normal and fatal concentrations. 
Among the 1 990 cases considered, oxycodone was detected in only 
fifteen cases. This result seems to indicate that the oxycodone crisis 
experienced in North America [35] has had a limited impact in 
Western Switzerland during the investigated period. 
4.2. Concentrations of benzodiazepine and benzodiazepine-like drugs 
Concentrations for 11 benzodiazepines and related substances 
(e.g. Z-drugs) were compiled, namely, alprazolam, bromazepam, 
clonazepam, diazepam, lorazepam, midazolam, nordiazepam, ox-
azepam, zolpidem, and zopiclone. One of the main challenges in the 
interpretation of benzodiazepine toxicology is the metabolism 
pathways known for the benzodiazepine family [36]. For example, 
the consumption of one medicine could lead to the detection of 
diazepam, nordiazepam and oxazepam in different ranges of con-
centration. Due to this metabolism pathways, it cannot be ruled that 
the benzodiazepine detected in whole blood are the result of one 
medicine or several. Among the 56 cases where diazepam is de-
tected, 52 contained nordiazepam and 41 oxazepam. While, in the 
253 cases where oxazepam is detected, 143 contained nordiazepam. 
In post-mortem toxicology investigations, the metabolism profiling 
is studied using the second matrix (if available). In the present study, 
only femoral blood results were considered and recorded. 
The benzodiazepine group shows the highest frequency of de-
tection (38%), but the substances rarely cause an intoxication alone 
(only 6 cases in group I, i.e. single substance poisoning). Regarding 
oxazepam, the median concentration in the single drug intoxication 
cases was ten times higher than the medians of the other groups. 
The reason why the median concentration of the group IIa cases is 
not higher might be explained by the subjective assessment of the 
results, where decisions to include low concentrations of oxazepam 
results in a low median. Concerning the other benzodiazepines and 
benzodiazepine-like drugs, most of them follow the oxazepam 
trend. The same trend is observed in group I for bromazepam, zol-
pidem, and zopiclone (concentrations in group I are ten times 
higher), while for cases not related to one substance only (groups IIa, 
IIb and III), the concentrations are in the same range. No intoxication 
from alprazolam, clonazepam, lorazepam and midazolam alone 
were reported during the period studied. These results suggest that 
the risk of fatal intoxication remains relatively low in comparison 
with the other benzodiazepines mentioned in this study. However, 
the interaction between benzodiazepine and other substances 
cannot be neglected and a study conducted in 2020, on the 
prescription of benzodiazepines in elderly people, suggests that 
benzodiazepine is overused among this population [37]. 
4.3. Stimulants and other drugs 
For MDMA and amphetamine, the concentration rate for the 10th 
percentile of group I is higher than the 90th percentile of group IIa. 
Therefore, the post-mortem concentration rate should be a reliable 
tool to interpret the cause of death. For cocaine, cases related to one- 
substance poisoning (group I) show high concentrations and almost 
no overlap with the other groups. For cases not related to one sub-
stance only (groups IIa, IIb and III), the concentrations are in the 
same range. For most of the cases, cocaine-related deaths occurred 
after prolonged periods of drug use. Due to this long period, cocaine 
could have already initiated a series of changes in molecular and 
metabolization process. This problem is known, and literature offers 
considerable toxicological data about cocaine-related deaths [38,39] 
which report that correlation between concentration and toxicity is 
not directly applicable. The overlap observed in our data concerning 
Table 1 (continued)           
Drug group N min 10th 25th median 75th 90th max  
Venlafaxine [µg/L] LLOQ 10 µg/L I  1 10 000 10 000 10 000 10 000 10 000 10 000 10 000 
IIa  11 67 270 535 940 1 650 2 000 2 100 
IIb  22 10 100 190 620 1 200 1 600 6 100 
III  15 50 83 120 230 420 565 950 
Total  49 10 92 183 455 1 125 1 790 10 000 
Zolpidem [µg/L] LLOQ 5.0 µg/L I  3 480 604 790 1 100 2 050 2 620 3 000 
IIa  40 5.0 13 33 88 298 947 2 000 
IIb  33 9.0 18 29 109 208 353 707 
III  36 5.0 5.0 9.0 19 47 92 270 
Total  112 5.0 9.0 18 52 200 580 3 000 
Zopiclone [µg/L] LLOQ 5.0 µg/L I  2 1 900 1 910 1 925 1 950 1 975 1 990 2 000 
IIa  21 8.0 11 22 32 135 324 1 200 
IIb  8 18 18 20 55 202 910 1 970 
III  7 10 15 21 23 34 45 59 
Total  38 8.0 14 21 34 185 975 2 000 
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groups other than one-substance poisoning confirms that for co-
caine more information is needed to assess conclusions rather than 
the blood concentration only. 
Regarding pentobarbital, all cases were assigned to a single sub-
stance intoxication (group I) (n = 7). In Switzerland, pentobarbital is 
mostly prescribed in protocols used to provide assistance to individuals 
wishing to end their own lives [40], as expected for these cases, con-
centration is the highest [6 280−35 000]. On the other hand, para-
cetamol is a very common medicine and sold over-the-counter in 
Switzerland. Consequently, even if paracetamol is frequently detected, it 
Fig. 2. Femoral blood concentrations of drugs in post-mortem cases, median concentration reported (µg/L). I) certified intoxication by one substance, IIa) certified intoxication by 
more than one substance, IIb) certified other causes of death with incapacitation due to drugs, and III) certified other causes of death without incapacitation due to drugs. In the 
boxplot, the whiskers are 1.5 times the interquartile range (IQR), and outliers are shown as circles. 
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is rarely quantified (only when the forensic pathologists request one). 
Therefore, only a limit range of concentration is reported in this study 
and mainly for the high values in groups I. 
For most drugs included in this study, the median concentration 
rate is higher in group I (single substance intoxication) than in the 
other three groups. In addition, 1.5 of the interquartile range between 
the group I and the other groups do not overlap. These concentrations 
could help to determine the range of concentration observed in 
post-mortem cases like reported from other studies [9,11]. 
4.4. Alcohol concentration 
The results of this study confirm and extend previous work 
showing that ethanol is the psychoactive substance most frequently 
identified in autopsy blood samples, either alone or together with 
other drugs [41–44]. Indeed, blood alcohol concentration exceeded 
0.10 [g/kg] for 25% of the cases. Herein, if we considered the cases 
attributed to alcohol intoxication only, the case distribution is ex-
tend is extend from concentration found in group III to highest 
concentration recorded (2.21–5.11 g/kg). However, this range relies 
on low number of cases (n = 12 for the group I) and thus, this result 
must be interpreted with caution. For the group IIa (intoxication 
attributed to alcohol in addition to other substances), the con-
centration observed (0.71–2.44 g/kg for 25th and 75th percentile) 
has a similar range as the two control groups (1.08–2.62 g/kg and 
0.35–1.62 g/kg, for IIb and III, respectively). These results can be 
explained by a variable tolerance to alcohol, but also to a variation in 
the subjective assessment of the possible contribution of a given 
alcohol concentration to the death in the intoxication cases. 
4.5. Comparison with previous work 
Jönsson, Druid and colleagues (2014) published post-mortem 
femoral blood concentrations of sedative and hypnotic drugs in a 
larger material in Sweden. Fig. 4 compares a few interesting 
substances (median) from their studies and the present one after 
applying a unit conversion of 1 000 µg/L to 1 µg/g. 
In this case, median concentrations for drugs included in both 
studies are often very close to each other. It can be observed that 
there are similar patterns for some substances between different 
groups, especially for alprazolam (IIa and III), clomethiazole (IIa), 
diazepam (III), nitrazepam (III), oxazepam (I and III), zolpidem (I and 
III), and zopiclone (III). However, there are some exceptions, such as 
the diazepam median concentration for group IIa. 
These differences can be explained partly by the limited number 
of cases in our study (e.g. one case with flunitrazepam for group IIa 
in our study versus 418 cases in the corresponding group in the 
study by Jönsson et al.). Another main reason for the observed dif-
ferences is the lower LOQ for most drugs in our study, since this 
results in the inclusion of a number of cases with very low con-
centrations, which will make the median lower. The LOQ will not 
affect the medians of the intoxications, hence the medians of groups 
I and IIa versus the medians of groups IIa and III should be expected 
to differ more when many low concentrations are included in the 
control groups. 
Finally, different practices in terms of drug consumption between 
Sweden and Switzerland could also explain this difference. For ex-
ample, prescription of diazepam is more frequent in Switzerland, 
even in low dose, so the median reported for the control groups 
(IIa and III) is really lower than in Sweden. To have a better overview 
of these, the reported the number of defined daily doses sold, as in 
Jönsson’s article [10], could allow to interpret in detail these differ-
ences. This result highlights the necessity to perform this approach in 
more than one country to see local specificities. If the usage and ha-
bits of consumers are different, some dissimilarities in the post- 
mortem concentrations could be expected. Jönsson and colleagues 
(2014) focused only on medicine, while herein, concentrations for 
illicit drugs, such as cocaine or MDMA, were provided as well. (Fig. 5). 
Another comparison was made with the Launiainen and 
Ojanperä’s study. As said in previous comparison, some differences 
could be explained by the low LOQ that affects the median drug 
concentrations. However, overall a good agreement is observed in 
both studies. Major gaps are observed for the amiodarone (C01BD01) 
and propofol (N01AX10) cases. These medications are involved in 
cardiac therapy and anaesthetic purposes. The gaps can be explained 
by the difference between sampling populations (by a factor 10). In 
this study, only a small number of cases contained these two sub-
stances (13 and 16 respectively). Moreover, the therapeutic range in 
plasma for amiodarone is 1–2 mg/L, while the median concentration 
range in post-mortem blood was found to be 3.4 mg/L. These dif-
ferences could be explained by the post-mortem redistribution 
phenomenon [45], already published for some beta blockers [46]. 
These results show the added value of such an approach and this 
Table 2 
Femoral blood concentration detailed for the four groups (g/kg). LLOQ: 0.10 [g/kg].           
[g/kg] N= min 10th percentile 25th percentile Median 75th percentile 90th percentile Max  
I  12  2.21  2.91  3.16  3.63  4.23  4.56  5.11 
IIa  95  0.10  0.19  0.71  1.28  2.07  2.44  3.92 
IIb  188  0.17  0.57  1.08  1.62  2.17  2.61  3.35 
III  169  0.10  0.16  0.35  0.71  1.17  1.62  2.1 
Total  464  0.10  0.20  0.47  1.20  1.96  2.49  5.11 
Fig. 3. Femoral blood alcohol concentration for the four groups (g/kg). I) certified 
intoxication by alcohol, IIa) certified intoxication by alcohol and one other substance, 
IIb) certified other causes of death with incapacitation due to alcohol, and III) certified 
other causes of death without incapacitation due to alcohol. 
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Fig. 4. Comparison of median post-mortem concentrations in our study and in the study by Jönsson & colleagues (2014) [10].  
Fig. 5. Comparison of median post-mortem concentrations between the present study and Launiainen and Ojanperä study (2014) [13]; horizontal categories are composed from 
the name of the substances and the number of cases from Launiainen study and the present study on the bracket, respectively. 
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strategy may assist pathologists and toxicologist in the interpreta-
tion process. 
4.6. Limitations 
The major limitations of this study were the recording methods 
and the strict inclusion of each case in one of the four groups. In fact, 
causes of deaths are attributed through toxicological analysis, cir-
cumstances of death and ascertainment performed by forensic pa-
thologists. In addition, considering that the cause of death (induced 
by one or several substances) was already based on the concentration 
value obtained during the toxicological analysis, a bias is induced. In 
this study, post-mortem cases were included by two independent 
reviewers, but some cases are tough to attribute to one of the four 
groups. In those cases, the original files were re-consulted, and a 
choice had to be made. 
Another limitation is the number of cases, which is quite low for 
statistical interpretation. Here, 1 990 cases were analysed, whereas 
Launiainen and Ojanperä [13] did a similar study with almost 58 000 
cases. A small number of cases indicate that the results (principally 
the concentration rate) should be interpreted with caution. This is 
especially true when the incriminated substance is present in only 
one case. For example, in the present study, there is only one case in 
group I for MDMA. Hence, interpretation needs to be carried out 
with caution. 
Finally, the concentrations in intoxication cases will be affected 
by a variety of factors, including, but not limited to, variations in 
time between intake and death resulting in a variable degree of 
metabolism of the parent drug, post-mortem interval, allowing for 
variable degree of post-mortem redistribution, and certain medical 
care treatments, as has previously been pointed out [38,39]. For 
example, the findings of morphine, fentanyl, ketamine and mid-
azolam may in some cases represent drug administration by health 
care staff. Another limitation of our study is the fact that for statis-
tical consideration (like the percentile) to be representative, the 
number of cases needs to be equal to, or exceed 5, and in this study 
we could not reach this number for several of the substances. 
Nevertheless, such an approach is already published and showed 
that the results were robust [9,10] and could be useful to help tox-
icologists and forensic pathologists in the interpretation process of 
post-mortem drug concentrations. The methodology should be ex-
tended to the whole country and even across Europe in order to 
increase the number of drugs for which post-mortem blood con-
centrations ranges are known, and in particular to increase the 
number of drugs for which fatal and non-fatal ranges are estab-
lished. This work is not only important for an appropriate determi-
nation of fatal intoxications, but also for pharmacovigilance, since it 
is crucial that the correct responsible drugs are identified and to 
avoid that substances which are not responsible are blamed. 
5. Conclusion 
In order to improve the interpretation of drug concentration in 
post-mortem toxicology investigation, an epidemiologic study was 
conducted based on a compilation of all cases between 2011 and 
2017 (1 990 cases) in Western Switzerland that involved tox-
icological investigations in femoral blood. Post-mortem femoral 
blood concentration were measured, and deaths were classified in 
four categories as previously published by Druid and Holmgren [27]: 
I – intoxication by one substance, IIa – intoxication by more than one 
substance, IIb – other causes of death with incapacitation due to 
drug consumption, III – other causes of death without incapacitation. 
Results show that most cases involve the male population with a 
median age of 50 years. More than half of the cases were attributed to 
group III (other causes of death with no incapacitation). The most 
common substances causing single-drug intoxication were morphine, 
methadone, ethanol, tramadol, and cocaine. 
Reference values for the most common 32 drugs detected in 
Switzerland between 2011 and 2017 are presented here. They have 
been used as cut-off values to differentiate normal vs fatal con-
centration of drugs detected in femoral blood in post-mortem cases. 
Even if no specific cut-off levels can be defined for fatal intoxication 
with any of the drugs, the medians and percentiles for each group 
offer a guidance to the forensic toxicologists and forensic pathologists 
as to which levels may be fatal and which ones most likely are not. 
The drug concentrations found in the different groups were similar to 
those reported for the same drugs in previous studies by Druid´s 
group, supporting the robustness to this strategy of selection, eva-
luation, and classification to obtain post-mortem femoral blood re-
ference concentrations of drugs. There were certain differences in 
concentrations for a number of drugs, which may partly be due to the 
low number of cases, and by the use of different LOQ, two factors that 
are important to take into account in further studies. Further research 
should involve a higher number of cases, for example by extending 
the study to broader geographical regions, in order to be able to es-
tablish post-mortem reference concentrations of substances for 
which there are scarce post-mortem toxicological data. 
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